Early screening is a valuable tool for detecting the presence of many types of cancer, even before the onset of symptoms or other signs of disease. This is particularly true in the screening of cervical cancer. In 2008, Professor Harald zur Hausen won the Nobel Prize in Physiology or Medicine for his discovery of the role of human papillomavirus (HPV) in cervical cancer. Cervical cancer is the second-most-common cancer affecting women worldwide and HPV is the main cause of this severe disease. Cervical cancer can easily be prevented as technologies are available to test for the cancer-causing types of HPV and determine if women may be at risk. QIAGEN provides the digene HPV Test, the leading test approved by the U.S. Food and Drug Administration (FDA) and CE-marked in Europe. The test directly detects the presence of high-risk types of the HPV virus. When used along with a Pap to screen women 30 and older, it more accurately identifies who is at risk of developing cervical cancer than the Pap alone. This is just one example of QIAGEN's solutions for women's healthcare.